INOVIO Pharmaceuticals (INO), a biotechnology company, on Wednesday announced positive data from its Phase 1/2 clinical trial of INO-3107, a potential treatment for recurrent respiratory papillomatosis or RRP.
The data, published in Nature Communications, showed that INO-3107 successfully induced new T cell populations that targeted airway and papilloma tissue, leading to a reduction in the need for surgeries.
In the trial, 81 percent of patients experienced a decrease in surgical interventions, with 28 percent of patients requiring no surgeries at all post-treatment.
These results highlight the potential of INO-3107 to provide a significant therapeutic option for RRP patients, who often undergo numerous surgeries due to the recurring growth of papillomas.
Based on these encouraging results, INOVIO plans to submit a biologics license application or BLA for INO-3107 in mid-2025, marking potential progress for the approval of the first DNA medicine for RRP.
The company remains optimistic about INO-3107's ability to transform the treatment paradigm for RRP and reduce the surgical burden for patients.
Currently, INO is trading at $1.94 up by 2.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.